Pathways' Pick of the Week: FDA Digs Deeper on Reimbursement

ARTICLE SUMMARY:

CDRH gets a seat on AMA reimbursement panels. Excerpted from Pathways’ Picks July 23: Shuren Steps Down, FDA’s Reimbursement Work, and Global Updates.

Market Pathways reported in May that FDA’s device center has recently been given a seat for a non-voting liaison on the American Medical Association’s CPT Editorial Panel and on the RVS Update Committee (RUC), two influential bodies in medtech reimbursement.

We have now confirmed that Douglas Kelly, MD , CDRH’s deputy director for science, has taken on that role. We spoke to Kelly about his participation in the panels and his broader push to bridge gaps between medtech regulatory and reimbursement silos, primarily in the context of the center’s evolving TPLC Advisory Program (TAP) pilot.

“What we're seeing is that a major problem across the ecosystem is the lack of a common vernacular,” Kelly says. “We want to make sure that we're all talking about the same thing. For the full article, see: “CDRH Steps Further Into Reimbursement Milieu.”

Continue reading Pathways’ Picks here.

Request to trial MyStrategist.com and?unlock 5-days of exclusive?subscriber-only access?to the medical device industry's most trusted strategic publications:?MedTech Strategist?&?Market Pathways.

Stay informed and get bonus content with our community newsletter by signing up here